B. Riley Comments on Vaxart's Q3 Earnings (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - B. Riley raised their Q3 2025 earnings estimates for shares of Vaxart in a report issued on Thursday, May 29th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn ($0.04) per share for the quarter, up from their prior estimate of ($0.07). B. Riley currently has a "Buy" rating and a $2.00 price objective on the stock. The consensus estimate for Vaxart's current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart's Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.14) EPS, FY2027 earnings at ($0.16) EPS and FY2028 earnings at ($0.02) EPS.

Separately, Wall Street Zen upgraded shares of Vaxart to a "hold" rating in a research note on Thursday, May 22nd.

Vaxart Price Performance

Shares of VXRT traded down $0.01 during mid-day trading on Monday, reaching $0.40. The company's stock had a trading volume of 1,235,455 shares, compared to its average volume of 2,447,787. Vaxart has a 12-month low of $0.29 and a 12-month high of $1.07. The stock has a market cap of $90.26 million, a PE ratio of -0.96 and a beta of 1.27. The company's 50 day moving average is $0.40 and its 200 day moving average is $0.55.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. The firm had revenue of $20.88 million for the quarter, compared to analyst estimates of $2.85 million.

Insider Activity at Vaxart

In other news, insider Steven Lo purchased 100,000 shares of the company's stock in a transaction that occurred on Monday, May 19th. The shares were purchased at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the purchase, the insider now directly owns 100,000 shares of the company's stock, valued at $49,000. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VXRT. Jones Financial Companies Lllp grew its position in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after acquiring an additional 478,111 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Vaxart by 95.0% during the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock worth $342,000 after acquiring an additional 251,789 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Vaxart during the fourth quarter worth approximately $129,000. Virtu Financial LLC purchased a new position in Vaxart during the 1st quarter worth $56,000. Finally, Silverarc Capital Management LLC grew its position in Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock worth $714,000 after purchasing an additional 77,782 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.